

TRADEMARK ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	RELEASE BY SECURED PARTY		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
Laminar Direct Capital, L.L.C.	FORMERLY Laminar Direct Capital, L.P.	04/25/2012	LIMITED LIABILITY COMPANY: DELAWARE
RECEIVING PARTY DATA			
Name:	Triax Pharmaceuticals, LLC		
Street Address:	20 Commerce Drive, Suite 232		
City:	Cranford		
State/Country:	NEW JERSEY		
Postal Code:	07016		
Entity Type:	LIMITED LIABILITY COMPANY: DELAWARE		
PROPERTY NUMBERS Total: 7			
Property Type	Number	Word Mark	
Registration Number:	3349628	TRIAx PHARMACEUTICALS	
Registration Number:	3320517	T3	
Registration Number:	3320516	T3	
Registration Number:	3150767	TRETIN X	
Registration Number:	0877677	MINOCIN	
Registration Number:	2136591	LOCOID LIPOCREAM	
Registration Number:	1058915	LOCOID	
CORRESPONDENCE DATA			
Fax Number:	6173426899		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	617-342-6803		
Email:	esimon@eckertseamans.com		
Correspondent Name:	Elizabeth M. Simon		
Address Line 1:	Two International Place, 16th Floor		

OP \$190.00 3349628

Address Line 2: Eckert Seamans Cherin & Mellott, LLC
Address Line 4: Boston, MASSACHUSETTS 02110

ATTORNEY DOCKET NUMBER: 294857-00002

NAME OF SUBMITTER: Elizabeth M. Simon

Signature: /Elizabeth M. Simon/

Date: 04/26/2012

Total Attachments: 3

source=TRIAx PHARMA - TERMINATION IN RELEASE OF TRADEMARKS (M1038204)#page1.tif

source=TRIAx PHARMA - TERMINATION IN RELEASE OF TRADEMARKS (M1038204)#page2.tif

source=TRIAx PHARMA - TERMINATION IN RELEASE OF TRADEMARKS (M1038204)#page3.tif

**TERMINATION AND RELEASE OF SECURITY INTEREST
IN TRADEMARKS**

This **TERMINATION AND RELEASE OF SECURITY INTEREST IN TRADEMARKS**, dated as of April 25, 2012 ("Release"), is made by Laminar Direct Capital, L.L.C., as successor in interest to Laminar Direct Capital, L.P., as Collateral Agent (the "Collateral Agent") in favor of Triax Pharmaceuticals, LLC (the "Grantor").

WHEREAS, pursuant to that certain Security and Pledge Agreement dated as of August 31, 2007 (as amended, restated, supplemented, modified, extended, renewed or replaced from time to time, the "Security Agreement") by and among the Obligor party thereto and the Collateral Agent, each Obligor granted to the Collateral Agent, for the ratable benefit of the Lenders, a continuing security interest in, and a right to set off against, any and all right, title and interest of such Obligor in, to, and under all the General Intangibles (including all contract rights and all patents, trademarks (including the goodwill associated therewith) and copyrights and applications for any of the foregoing) and Proceeds of the foregoing;

WHEREAS, pursuant to the Security Agreement, Grantor, an Obligor, executed and delivered to Collateral Agent, for the ratable benefit of the Lenders, the Notice of Grant of Security Interest in Trademarks dated as of August 31, 2007 ("Notice"); and

WHEREAS, the Notice was recorded at the United States Patent and Trademark Office ("USPTO") on September 25, 2007 at Reel 3627 Frame 0111.

NOW THEREFORE, in consideration of the mutual promises and undertakings set forth herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and with the intention of being legally bound hereby, Collateral Agent, on behalf of the Lenders, and Grantor (the "parties") agree as follows:

SECTION 1. Defined Terms. All capitalized terms used herein but not otherwise defined herein have the meanings given to them in the Security Agreement or Notice.

SECTION 2. Termination and Release. Collateral Agent, on behalf of the Lenders, without representation, warranty, or recourse, hereby:

(a) terminates, cancels, discharges, and releases the mortgage, pledge, and hypothecation and lien on and security interest in and to the right, title, and interest in, to, and under all the Obligor's General Intangibles (including all contract rights and all patents, trademarks (including the goodwill associated therewith) and copyrights and applications for any of the foregoing) and Proceeds of the foregoing, including the foregoing listed on Schedule A attached hereto; and

(b) authorizes the recordation of this Release with the USPTO.

IN WITNESS WHEREOF, the Collateral Agent, on behalf of the Lenders, has caused this Termination and Release of Security Interest in Trademarks to be duly executed as of the date first set forth above.

Collateral Agent:

Laminar Direct Capital, L.L.C.,
as successor in interest to Laminar Direct Capital, L.P.
as Collateral Agent

By: Robert T. Ladd
Name: Robert T. Ladd
Title: Authorized Signatory

Termination and Release of Security Interest in Trademarks

Schedule A

**Triax Pharmaceuticals, LLC
(Delaware LLC)**

U.S. Trademarks

Registered Marks

Mark	Registration No.	Registration Date
TRIAx PHARMACEUTICALS	3349628	12/04/07
T3	3320517	10/23/07
T3	3320516	10/23/07
TRETIN X	3150767	10/03/06
MINOCIN	0877677	09/30/69
LOCOID	2136591	02/17/98
LOCOID LIPOCREAM	1058915	02/15/77